Oxford Cancer Biomarkers

oxford cancer biomarkers is a spin-out of oxford university. the company is closely affiliated with the institute of cancer medicine, where its founders lead international research groups focused on translational cancer science. oxford cancer biomarkers was incorporated in 2011 and secured a corporate partnership with quintiles in early 2012. this included an investment of £3m for an equity stake by quintiles. oxford cancer biomarkers works hand-in-hand with partner companies to provide companion biomarker diagnostic tests that help target the drug to responsive patients. the company’s biomarker platform, cancernav™, enables the isolation of cancer biomarkers that align with drug response. in the clinical context patients can be identified that will undergo the best therapeutic effect from being treated with the drug.